Systemic light chain (AL) amyloidosis is a protein misfolding disorder characterized by the
deposition of abnormal immunoglobulin light chains in fibrillary aggregates, resulting in end …

In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell
clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the …

Primary systemic light chain amyloidosis (AL) is a rare monoclonal plasma cell disorder.
Much research has been performed to determine the factors that underly amyloidogenicity …

Immunoglobulin light-chain (AL) amyloidosis is a clonal plasma cell dyscrasia. Delay in
diagnosis is the major hurdle in improving the outcomes of AL patients. Almost all patients …

Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is
associated with an underlying plasma cell dyscrasia. The disease often is difficult to …

In amyloid light-chain (AL) amyloidosis, a small plasma-cell clone, or less frequently a
mature B-cell clone, produces toxic monoclonal light chains that can be deposited in the …

Systemic light chain (AL) amyloidosis is a rare plasma cell neoplasm caused by misfolded
protein deposition resulting in organ dysfunction. High-dose melphalan with autologous …

Improvement in survival in Light chain (AL) amyloidosis has been seen over recent decades,
enabling more patients to achieve long‐term survival. Patients with AL amyloidosis who …

Introduction Immunoglobulin light chain amyloidosis (AL Amyloidosis) is a monoclonal
plasma cell proliferative disorder that is characterized by tissue deposits of misfolded …

Despite significant progress and improving outcomes in the management of plasma cell
disorders, AL amyloidosis remains diagnostically and therapeutically challenging for …